Elanco Animal Health: 3 Key Takeaways for Long-Term Investors
Key Points
Third-quarter organic constant currency revenue grew 9% year over year.
Elanco Animal Health lowered gross debt by $216 million in Q3.
Innovation products generated $328 million in third quarter revenue.
- Motley Fool Issues Rare "Total Conviction" Buy Alert ›
On its third-quarter 2026 earnings call, held on Nov. 6, 2026, Elanco Animal Health (NYSE:ELAN) announced revenue grew 11% year over year to $1.265 billion. Balance sheet deleveraging and pricing power are lifting operating margins while new veterinary treatments gain market share.
Three takeaways from the call highlight how management plans to capture long-term growth.
1. Debt Reduction Unlocks Capital Allocation Flexibility
Lowering gross debt by $216 million in the third quarter brought net leverage below 3.0 times earnings before interest, taxes, depreciation, and amortization (EBITDA), meeting a key balance sheet target ahead of schedule. Improving free cash flow gives Elanco Animal Health greater room to fund organic growth initiatives.
Achieving the sub-3.0 times milestone accelerates our capital allocation flexibility, we advance toward our target of 2 to 2.5x.
-- Robert VanHimbergen, Executive Vice President and Chief Financial Officer
2. Differentiated Innovation Drives Pricing Power Over Discounting
Pet health product prices increased by 5% in the third quarter, while volume rose by 9%, indicating that proprietary treatments command full value in the clinic. Management is avoiding price cuts even as industry rivals use temporary promotional discounts.
Elanco has not, will not, and does not expect a need for our participation in aggressive price competition to grow and gain share.
-- Jeffrey N. Simmons, President and Chief Executive Officer
3. Efficiency Programs Target Long-Term Savings to Expand Margins
The Elanco Ascend initiative aims to improve profitability through procurement savings, operational automation, and artificial intelligence in research and development. These measures helped expand adjusted gross margin three percentage points to 56.1% in the quarter.
[We] continue to advance our Elanco Ascend productivity initiatives, targeting $200 million to $250 million in total adjusted EBITDA savings by 2030.
-- Robert VanHimbergen, Executive Vice President and Chief Financial Officer
Looking Ahead
Momentum is building across key treatment categories as new veterinary launches expand clinic penetration. Operational scale and a diversified portfolio spanning farm animals and pets provide structural growth drivers, while management watches regional livestock cycles and inflation pressures.
We have made rapid progress to gain a foothold in the broad spectrum in decto and derm, with each market over $2 billion in size.
-- Jeffrey N. Simmons, President and Chief Executive Officer
Expanding distribution partnerships and continuous manufacturing improvements position the business to capture long-term market share.
We have a long runway to win share while the markets continue to grow.
-- Jeffrey N. Simmons, President and Chief Executive Officer
Should you buy stock in Elanco Animal Health right now?
Before you buy stock in Elanco Animal Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Elanco Animal Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $341,966!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,146,819!*
Now, it’s worth noting Stock Advisor’s total average return is 852% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 9, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
